Get to know our clinical trials
Clinical trial of botensilimab (AGEN1181) in monotherapy and in combination with balstilimab (AGEN2034) or with investigator's choice of reference therapy (regorafenib or trifluridine and tipiracil) for the treatment of metastatic colorectal cancer.
THE GOAL OF THIS STUDY IS TO LEARN WHETHER A NEW TYPE OF IMMUNE-BASED TREATMENT CALLED BOTENSILIMAB (ALSO KNOWN AS AGEN1181), ALONE OR TOGETHER WITH BALSTILIMAB (ALSO KNOWN AS AGEN2034), CAN HELP PATIENTS WITH RCC WITHOUT IMS-A/DMMR.
Status
In recruitment
headquarters
Madrid
Technical Summary
- PHASE II, RANDOMIZED, UNBLINDED, PHASE II STUDY OF BOTENSILIMAB (AGEN1181) IN MONOTHERAPY AND IN COMBINATION WITH BALSTILIMAB (AGEN2034) OR WITH INVESTIGATOR'S CHOICE OF REFERENCE THERAPY (REGORAFENIB OR TRIFLURIDINE AND TIPIRACIL) FOR THE TREATMENT OF REFRACTORY METASTATIC COLORECTAL CANCER. IMMUNOTHERAPY
- Code EudraCT: 2022-502065-23
- Protocol number: C-800-25
- Promoter: Agenus Inc.
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.